Volume 35, No 3, Mar 2025
ISSN: 1001-0602
EISSN: 1748-7838 2018
impact factor 17.848*
(Clarivate Analytics, 2019)
Volume 35 Issue 3, March 2025: 220-223 | Open Access
LETTERS TO THE EDITOR
Fourth-generation chimeric antigen receptor T-cell therapy is tolerable and efficacious in treatment-resistant rheumatoid arthritis
Yujing Li1,† , Sujun Li2,† , Xiaojuan Zhao1,† , Jun Sheng3 , Lei Xue2 , Georg Schett4 , Ce Shi5 , Biliang Hu5,†,* , Xingbing Wang6,†,* , Zhu Chen1,†,*
1Department of Rheumatology and Immunology, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China
2Department of Hematology, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China
3Department of Rheumatology and Immunology, the First Affiliated Hospital of Wannan Medical College, Wuhu, Anhui, China
4Department of Internal Medicine 3, Rheumatology and Immunology, Friedrich Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany
5Siweikang Therapeutics, Changsha, Hunan, China
6Department of Hematology, Centre for Leading Medicine and Advanced Technologies of IHM, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China
†These authors contributed equally: Yujing Li, Sujun Li, Xiaojuan Zhao
†These authors jointly supervised this work: Biliang Hu, Xingbing Wang, Zhu Chen
Correspondence: Biliang Hu(bilianghu@celledit.com)Xingbing Wang(wangxingbing@ustc.edu.cn)Zhu Chen(doczchen@ustc.edu.cn)
https://doi.org/10.1038/s41422-024-01068-2
FULL TEXT | PDF
Browse 281
